Expertise in
38
conditions

Dr. Varun Monga

Oncology
University Of Iowa Stead Family Children's Hospital
200 Hawkins Dr, 
Iowa City, IA 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Expertise in
38
conditions
University Of Iowa Stead Family Children's Hospital
200 Hawkins Dr, 
Iowa City, IA 

Overview

Varun Monga is an Oncologist practicing medicine in Iowa City, Iowa.

Dr. Monga is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Astrocytoma, Glioblastoma, Fibrosarcoma, and Splenectomy.

He is actively involved in clinical research, co-authoring 76 peer reviewed articles and participating in 21 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Ucsf Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

University of Iowa Stead Family Children's Hospital
200 Hawkins Dr, Iowa City, IA 52242

Additional Areas of Focus

Dr. Monga has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: June 02, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Enrollment Status: Recruiting
Publish Date: March 03, 2026
Intervention Type: Biological
Study Phase: Phase 1
Phase 1b/2 Neoadjuvant High Dose Ascorbate With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas of Extremity, Trunk and Retroperitoneum
Phase 1b/2 Neoadjuvant High Dose Ascorbate With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas of Extremity, Trunk and Retroperitoneum
Enrollment Status: Completed
Publish Date: June 18, 2026
Intervention Type: Drug
Study Drug: Ascorbate
Study Phase: Phase 1/Phase 2
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Telaglenastat Hydrochloride, Temozolomide
Study Phase: Phase 1
A Pilot Study of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults
A Pilot Study of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults
Enrollment Status: Active_not_recruiting
Publish Date: May 22, 2026
Intervention Type: Drug
Study Drug: Ascorbate
Study Phase: Early Phase 1
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Enrollment Status: Active_not_recruiting
Publish Date: May 01, 2026
Intervention Type: Other, Drug
Study Drugs: Cabozantinib, Temozolomide
Study Phase: Phase 2
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Completed
Publish Date: April 22, 2026
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2026
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Locally Advanced or Metastatic Solid Tumors With IDH Mutations
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Locally Advanced or Metastatic Solid Tumors With IDH Mutations
Enrollment Status: Terminated
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drug: HMPL-306
Study Phase: Phase 1
View 8 Less Clinical Trials

76 Total Publications

Targeting of Wnt-β-Catenin Pathway in Recurrent Ameloblastoma.
Targeting of Wnt-β-Catenin Pathway in Recurrent Ameloblastoma.
Journal: The New England journal of medicine
Published: June 03, 2026
Similar Doctors
Expertise in
15
conditions
Dr. Yousef Zakharia
Oncology
Expertise in
15
conditions
Dr. Yousef Zakharia
Oncology
Referral may be required

University Of Iowa Stead Family Children's Hospital

200 Hawkins Dr, 
Iowa City, IA 
 (1654.3 miles away)
319-356-1616
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Yousef Zakharia is an Oncologist practicing medicine in Iowa City, Iowa. Dr. Zakharia is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Melanoma, and Orchiectomy.

Expertise in
15
conditions
Dr. David Bender
Oncology
Expertise in
15
conditions
Dr. David Bender
Oncology
Referral may be required

University Of Iowa Stead Family Children's Hospital

200 Hawkins Dr, 
Iowa City, IA 
 (1654.3 miles away)
319-356-2015
Languages Spoken:
English
See accepted insurances

David Bender is an Oncologist practicing medicine in Iowa City, Iowa. Dr. Bender is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Endometrial Stromal Sarcoma, Hysterectomy, and Bladder Reconstruction.

Expertise in
16
conditions
Dr. Michael Goodheart
Oncology
Expertise in
16
conditions
Dr. Michael Goodheart
Oncology
Referral may be required

University Of Iowa Stead Family Children's Hospital

200 Hawkins Dr, 
Iowa City, IA 
 (1654.3 miles away)
319-356-2015
Languages Spoken:
English
See accepted insurances

Michael Goodheart is an Oncologist practicing medicine in Iowa City, Iowa. Dr. Goodheart is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Vulvar Cancer, Hysterectomy, and Hernia Surgery.

Frequently Asked Questions about Dr. Varun Monga

How do I make an appointment with Dr. Varun Monga?

You can book an appointment with Dr. Varun Monga by calling their office at 319-356-4019. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Varun Monga a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Varun Monga is classified as an Elite expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Varun Monga specialize in?

While Dr. Varun Monga is a Oncology, they have specific expertise in Adult Soft Tissue Sarcoma, Astrocytoma, and Glioblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Varun Monga participate in research or clinical trials?

Yes. Dr. Varun Monga has published 76 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Dr. Varun Monga's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Varun Monga accept my insurance?

Dr. Varun Monga accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 319-356-4019 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Monga's expertise for a condition
ConditionClose
View All 26 Distinguished Conditions
View All 7 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile